Figure 1From: Antitumour activity of a potent MEK inhibitor RDEA119/BAY 869766 combined with rapamycin in human orthotopic primary pancreatic cancer xenografts Characterization of orthotopic primary pancreatic cancer xenografts. Representative H&E and immunohistochemical staining of p53 and phosphorylated ERK in 3 orthotopic primary pancreatic cancer xenografts. The scale bar represents 100 μm.Back to article page